SWOG clinical trial number
S1400K

A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

64% Accrual
Accrual
64%
Closed
Phase
64% Accrual
Accrual
64%
Abbreviated Title
Lung-MAP S1400K: c-MET Positive
Status Notes
Effective on 12/21/18, S1400K will be permanently closed to accrual.

Effective on 10/18/18 at 1:00 pm PST, S1400K will be temporarily closed to accrual.

Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Activated
02/05/2018
Closed
12/21/2018
Participants
NCORP, Members, Medical Oncologists, Pathologists, CTSU, Affiliates, CCTG

Research committees

Lung Cancer

Treatment

ABBV-399

Other Study Materials

Other Clinical Trials

S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
1% Accrual
Accrual
1%
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number